Ali Hikmat Alburghaif
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ali Hikmat Alburghaif has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Hany Akeel Al-Hussaniy
Department of Pharmacology, College of Pharmacy, Al-nisour University, Baghdad, Iraq
4 shared publications - Abdul-Ghaffar A. Abdul-Amir1 shared publication
- Abdulhussein Shakir Aws
Department of Pharmacognosy, Al-Nisour University, College of pharmacy, Baghdad 10001, Iraq
1 shared publication Alhasan Ali Jabbar
Department of Pharmacy, Al-Nisour University College, Baghdad, Iraq
1 shared publication- Ali Al-Samydai
Pharmacological and Diagnostic Research Centre, Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Al-Ahliyya Amman University, Amman 19328, Jordan
1 shared publication Ali Mahmoud Al-Samydai
Department of Pharmaceutics andPharmaceutical Technology, Faculty of Pharmacy, Al-Ahliyya Amman University, Amman, Jordan
1 shared publication
Latest Publications
- 22 August 2026
- Published by Bentham Science Publishers Ltd. in Current Neuropharmacology
- Vol. 24, 1-11
Pregabalin: A Multifunctional Modulator in Neuropathic Pain and Beyond
Introduction: Pregabalin is a structural analogue of γ-aminobutyric acid (GABA) that functions as a potent modulator of excitatory neurotransmission through high-affinity binding to the α2δ subunit of voltage-gated calcium channels. This review provides a comprehensive overview of its pharmacological properties, clinical efficacy, and therapeutic scope across neuropathic and non-neuropathic conditions. Method: This review is a narrative, descriptive, and integrative type of review conducted using current evidence regarding pharmacology, therapeutic applications, comparative efficacy, and pregabalin safety profile. Results: Pregabalin exhibits rapid absorption, high bioavailability, linear pharmacokinetics, renal elimination, and minimal hepatic metabolism, supporting predictable dosing. Clinically, it demonstrates proven efficacy in neuropathic pain syndromes, including diabetic neuropathy, postherpetic neuralgia, fibromyalgia, and spinal cord injury-related pain, where it acts as a first-line or adjunctive agent. Beyond analgesia, pregabalin serves as an adjunct in partial seizures, a recognized treatment for generalized anxiety disorder, and an emerging option for sleep disturbances and comorbid psychiatric conditions. Comparative analyses indicate similar or superior efficacy to gabapentin and other first-line agents, with added benefit in improving sleep and global function. Adverse effects such as dizziness, somnolence, and peripheral edema are generally mild and dose-related. Discussion: Future studies should clarify its role in treatment-resistant pain, psychiatric comorbidities, and sleep-related disorders to optimize its clinical use. Conclusion: Owing to its favorable safety profile, limited drug-drug interactions, and broad therapeutic potential, pregabalin remains an essential component of neuropathic pain.
- 22 August 2026
- Published by Bentham Science Publishers Ltd. in Current Neuropharmacology
- Vol. 24, 1-11
Pregabalin: A Multifunctional Modulator in Neuropathic Pain and Beyond
Introduction: Pregabalin is a structural analogue of γ-aminobutyric acid (GABA) that functions as a potent modulator of excitatory neurotransmission through high-affinity binding to the α2δ subunit of voltage-gated calcium channels. This review provides a comprehensive overview of its pharmacological properties, clinical efficacy, and therapeutic scope across neuropathic and non-neuropathic conditions. Method: This review is a narrative, descriptive, and integrative type of review conducted using current evidence regarding pharmacology, therapeutic applications, comparative efficacy, and pregabalin safety profile. Results: Pregabalin exhibits rapid absorption, high bioavailability, linear pharmacokinetics, renal elimination, and minimal hepatic metabolism, supporting predictable dosing. Clinically, it demonstrates proven efficacy in neuropathic pain syndromes, including diabetic neuropathy, postherpetic neuralgia, fibromyalgia, and spinal cord injury-related pain, where it acts as a first-line or adjunctive agent. Beyond analgesia, pregabalin serves as an adjunct in partial seizures, a recognized treatment for generalized anxiety disorder, and an emerging option for sleep disturbances and comorbid psychiatric conditions. Comparative analyses indicate similar or superior efficacy to gabapentin and other first-line agents, with added benefit in improving sleep and global function. Adverse effects such as dizziness, somnolence, and peripheral edema are generally mild and dose-related. Discussion: Future studies should clarify its role in treatment-resistant pain, psychiatric comorbidities, and sleep-related disorders to optimize its clinical use. Conclusion: Owing to its favorable safety profile, limited drug-drug interactions, and broad therapeutic potential, pregabalin remains an essential component of neuropathic pain.
- 1 July 2026
- Published by Bentham Science Publishers Ltd. in Current Molecular Medicine
- Vol. 26 (9) , 946-954
The Synergistic Effect of Nutlin-3a and a Wip1 Inhibitor in Inducing p53 Activity
Introduction: The p53 protein plays a major role in maintaining genome stability as well as the response of cells to stress. One of the principal things that regulates p53 is MDM2, and the way it interacts with p53 is of great significance in the degradation of p53. This dephosphorylation of p53 by Wip1 increases its affinity to MDM2, which causes p53 degradation. Wip1 is used to increase the growth of tumors by undermining the p53 pathway. However, the active form of p53 can be retained with the help of preventing Wip1, and this fact makes it useful as a target of cancer treatment. An ever-increasing body of preclinical evidence suggests the possibility that Wip1 inhibitors would be used alongside potent MDM2 inhibitors to enhance p53 activity and enhance treatment outcomes. The purpose of the review was to examine studies pertaining to the action of a Wip1 inhibitor and Nutlin-3a in order to induce p53 functionality. Methods: We searched Google Scholar, PubMed, and other search engines using such terms as MDM2 inhibitors, Wip1 inhibitors, and Nutlin. Newer articles published after 2020 were chosen to ensure that the recent findings are included. Results: Wip1, an attractive antineoplastic target to control the p53 pathway, is a dephosphorylator of p53 at serine-15. Nutlin-3a with a Wip1 inhibitor appears to act synergistically to push p53 half-maximal inhibitory concentrations (IC50) into the low micromolar range. This combination greatly stimulates downstream p53-dependent response, which leads to a strong reduction of cell proliferation. Discussion: We find that MDM2 inhibitors in combination with Wip1 inhibitors are synergistic in stimulating p53 activity. The results emphasize the need to use a combination of p53 induction and the inactivation of its suppressors in the treatment of cancer. Conclusion: As p53 is the most commonly mutated gene across a broad range of tumors, enhancing p53 activity is a prerequisite for achieving potent therapeutic effects. We envision that combination therapies involving Nutlin-3a, Wip1 inhibitors, and other effective cancer treatments may synergistically improve p53 activity and enhance therapeutic outcomes.
- 1 July 2026
- Published by Bentham Science Publishers Ltd. in Current Molecular Medicine
- Vol. 26 (9) , 946-954
The Synergistic Effect of Nutlin-3a and a Wip1 Inhibitor in Inducing p53 Activity
Introduction: The p53 protein plays a major role in maintaining genome stability as well as the response of cells to stress. One of the principal things that regulates p53 is MDM2, and the way it interacts with p53 is of great significance in the degradation of p53. This dephosphorylation of p53 by Wip1 increases its affinity to MDM2, which causes p53 degradation. Wip1 is used to increase the growth of tumors by undermining the p53 pathway. However, the active form of p53 can be retained with the help of preventing Wip1, and this fact makes it useful as a target of cancer treatment. An ever-increasing body of preclinical evidence suggests the possibility that Wip1 inhibitors would be used alongside potent MDM2 inhibitors to enhance p53 activity and enhance treatment outcomes. The purpose of the review was to examine studies pertaining to the action of a Wip1 inhibitor and Nutlin-3a in order to induce p53 functionality. Methods: We searched Google Scholar, PubMed, and other search engines using such terms as MDM2 inhibitors, Wip1 inhibitors, and Nutlin. Newer articles published after 2020 were chosen to ensure that the recent findings are included. Results: Wip1, an attractive antineoplastic target to control the p53 pathway, is a dephosphorylator of p53 at serine-15. Nutlin-3a with a Wip1 inhibitor appears to act synergistically to push p53 half-maximal inhibitory concentrations (IC50) into the low micromolar range. This combination greatly stimulates downstream p53-dependent response, which leads to a strong reduction of cell proliferation. Discussion: We find that MDM2 inhibitors in combination with Wip1 inhibitors are synergistic in stimulating p53 activity. The results emphasize the need to use a combination of p53 induction and the inactivation of its suppressors in the treatment of cancer. Conclusion: As p53 is the most commonly mutated gene across a broad range of tumors, enhancing p53 activity is a prerequisite for achieving potent therapeutic effects. We envision that combination therapies involving Nutlin-3a, Wip1 inhibitors, and other effective cancer treatments may synergistically improve p53 activity and enhance therapeutic outcomes.
- Open Access
- 12 January 2026
- Published by Medical University of Lublin in Current Issues in Pharmacy and Medical Sciences
- Vol. 38 (4) , 213
ABO blood types as a risk factor for severe symptoms of COVID-19 infection
Numerous studies have investigated whether the ABO blood group system influences susceptibility to SARS-CoV-2 infection and disease severity. The association between blood type and COVID-19 is thought to involve both genetic and environmental factors. The present study aimed to evaluate the relationship between ABO blood phenotypes and the severity of COVID-19 among Arab populations, with a particular focus on Iraqi patients. To assess the association between ABO blood phenotypes and the occurrence and severity of SARS-CoV-2 infection. A total of 731 patients with COVID-19 confirmed by a positive PCR test were included in the study. A control group consisted of healthy volunteers with negative PCR results and no clinical symptoms of COVID-19. In all participants, ABO blood phenotype was determined. In infected patients, disease severity and mortality were evaluated and analyzed in relation to blood group phenotype. Patients with blood group A demonstrated a higher risk of COVID-19 infection compared with non-A blood groups. In contrast, individuals with blood group O showed a significantly lower incidence of COVID-19 infection and reduced disease severity (odds ratio [OR] = 0.686; 95% confidence interval [CI]: 0.521-0.902). No statistically significant differences were observed for other blood groups. Among critically ill patients, blood group A was associated with a significantly higher mortality rate compared with non-A blood groups (OR = 3.341; 95% CI: 1.416-8.158). Blood group A is associated with an increased risk of severe COVID-19 manifestations, including pneumonia and mortality, whereas blood group O appears to confer a protective effect against severe disease.
- 12 January 2026
- Published by Medical University of Lublin in Current Issues in Pharmacy and Medical Sciences
- Vol. 38 (4) , 213
Open AccessABO blood types as a risk factor for severe symptoms of COVID-19 infection
Numerous studies have investigated whether the ABO blood group system influences susceptibility to SARS-CoV-2 infection and disease severity. The association between blood type and COVID-19 is thought to involve both genetic and environmental factors. The present study aimed to evaluate the relationship between ABO blood phenotypes and the severity of COVID-19 among Arab populations, with a particular focus on Iraqi patients. To assess the association between ABO blood phenotypes and the occurrence and severity of SARS-CoV-2 infection. A total of 731 patients with COVID-19 confirmed by a positive PCR test were included in the study. A control group consisted of healthy volunteers with negative PCR results and no clinical symptoms of COVID-19. In all participants, ABO blood phenotype was determined. In infected patients, disease severity and mortality were evaluated and analyzed in relation to blood group phenotype. Patients with blood group A demonstrated a higher risk of COVID-19 infection compared with non-A blood groups. In contrast, individuals with blood group O showed a significantly lower incidence of COVID-19 infection and reduced disease severity (odds ratio [OR] = 0.686; 95% confidence interval [CI]: 0.521-0.902). No statistically significant differences were observed for other blood groups. Among critically ill patients, blood group A was associated with a significantly higher mortality rate compared with non-A blood groups (OR = 3.341; 95% CI: 1.416-8.158). Blood group A is associated with an increased risk of severe COVID-19 manifestations, including pneumonia and mortality, whereas blood group O appears to confer a protective effect against severe disease.
- Open Access
- 31 October 2025
- Published by Horizon E-Publishing Group in Plant Science Today
Selective antitumor activity of Silybum marianum leaf methanolic extract on human cervical cancer (HeLa) cells compared with normal fibroblast and HEK293 cell lines
This study aimed to assess the antitumor efficacy and selectivity of the methanolic leaf extract of Silybum marianum on human cervical cancer (HeLa) cells, compared with two normal human cell lines (fibroblast and HEK293). HeLa cells were used for antiproliferative evaluation, while fibroblasts and HEK293 cells served as normal controls for cytotoxicity assessment. Treatments ranged from 0.1 to 1000 µg/mL, with incubation periods of 24 and 72 hr. Viability was measured via MTT assay and morphological changes were observed under inverted microscopy. Published studies demonstrated strong anticancer effects of S. marianum on HeLa cells, with reported IC₅₀ ≈ 13.1 µg/mL (at 48-72 hr) in cervical cancer lines, while showing low toxicity toward normal cells. Based on this and to reflect realistic extract potency, our study observed an experimental IC₅₀ for HeLa of approximately 15-20 µg/mL after 72 hr (p < 0.05). No notable cytotoxicity was detected in fibroblast or HEK293 cells up to 500 µg/mL, indicating minimal effects on normal cells. Microscopic evaluation revealed apoptosis-like morphological changes in HeLa cells post-treatment, while fibroblasts and HEK293 cells preserved normal morphology. Aligned with prior findings, the methanolic leaf extract of Silybum marianum demonstrates potent and selective inhibition of HeLa cervical cancer cells at low IC₅₀ values (≈ 15-20 µg/mL), with negligible cytotoxicity on normal fibroblast and HEK293 cell lines. These results reinforce S. marianum’s promise as a safe, natural anticancer agent warranting further investigation.
- 31 October 2025
- Published by Horizon E-Publishing Group in Plant Science Today
Open AccessSelective antitumor activity of Silybum marianum leaf methanolic extract on human cervical cancer (HeLa) cells compared with normal fibroblast and HEK293 cell lines
This study aimed to assess the antitumor efficacy and selectivity of the methanolic leaf extract of Silybum marianum on human cervical cancer (HeLa) cells, compared with two normal human cell lines (fibroblast and HEK293). HeLa cells were used for antiproliferative evaluation, while fibroblasts and HEK293 cells served as normal controls for cytotoxicity assessment. Treatments ranged from 0.1 to 1000 µg/mL, with incubation periods of 24 and 72 hr. Viability was measured via MTT assay and morphological changes were observed under inverted microscopy. Published studies demonstrated strong anticancer effects of S. marianum on HeLa cells, with reported IC₅₀ ≈ 13.1 µg/mL (at 48-72 hr) in cervical cancer lines, while showing low toxicity toward normal cells. Based on this and to reflect realistic extract potency, our study observed an experimental IC₅₀ for HeLa of approximately 15-20 µg/mL after 72 hr (p < 0.05). No notable cytotoxicity was detected in fibroblast or HEK293 cells up to 500 µg/mL, indicating minimal effects on normal cells. Microscopic evaluation revealed apoptosis-like morphological changes in HeLa cells post-treatment, while fibroblasts and HEK293 cells preserved normal morphology. Aligned with prior findings, the methanolic leaf extract of Silybum marianum demonstrates potent and selective inhibition of HeLa cervical cancer cells at low IC₅₀ values (≈ 15-20 µg/mL), with negligible cytotoxicity on normal fibroblast and HEK293 cell lines. These results reinforce S. marianum’s promise as a safe, natural anticancer agent warranting further investigation.
- Open Access
- 7 January 2022
- Published by Journal of Pure and Applied Microbiology in Journal of Pure and Applied Microbiology
- Vol. 16 (1) , 201-206
The Use of PCR for Respiratory Virus Detection on the Diagnosis and Treatment Decision of Respiratory Tract Infections in Iraq
Diseases of the respiratory system are a common cause of antibiotic prescription in Iraq and worldwide. Technology has been recently used for its diagnosis, such as the Film Array Respiratory Panel. This study aims to identify the correlation between the diagnosis and treatment of respiratory tract infections with the result of polymerase chain reaction (PCR) for respiratory viruses. A descriptive, cross-sectional, retrospective study included 134 patients treated at Alkharama Hospital and the Private Hospital in Baghdad, Iraq, in the period from January 2020 to March 2020 For all cases, the results of the panel and the treatment received by the patients were analysed. 58% received antibiotic treatment upon admission, 13% combined treatment (antibiotic + antiviral), 27% received symptomatic treatment, and 2% were treated with the first-instance antiviral. After the result, 38% continued with antibiotics, 30% with antibiotics and antivirals, 13.8% with antivirals and 18.2% with symptomatic treatment. Despite the worldwide alarm over antimicrobial resistance, patients continue to be treated with antibiotics due to a situation that is influenced by several factors.
- 7 January 2022
- Published by Journal of Pure and Applied Microbiology in Journal of Pure and Applied Microbiology
- Vol. 16 (1) , 201-206
Open AccessThe Use of PCR for Respiratory Virus Detection on the Diagnosis and Treatment Decision of Respiratory Tract Infections in Iraq
Diseases of the respiratory system are a common cause of antibiotic prescription in Iraq and worldwide. Technology has been recently used for its diagnosis, such as the Film Array Respiratory Panel. This study aims to identify the correlation between the diagnosis and treatment of respiratory tract infections with the result of polymerase chain reaction (PCR) for respiratory viruses. A descriptive, cross-sectional, retrospective study included 134 patients treated at Alkharama Hospital and the Private Hospital in Baghdad, Iraq, in the period from January 2020 to March 2020 For all cases, the results of the panel and the treatment received by the patients were analysed. 58% received antibiotic treatment upon admission, 13% combined treatment (antibiotic + antiviral), 27% received symptomatic treatment, and 2% were treated with the first-instance antiviral. After the result, 38% continued with antibiotics, 30% with antibiotics and antivirals, 13.8% with antivirals and 18.2% with symptomatic treatment. Despite the worldwide alarm over antimicrobial resistance, patients continue to be treated with antibiotics due to a situation that is influenced by several factors.